Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer Subside Monsanto...

    Bayer Subside Monsanto India appoints Cherukuri Ravishankar as new MD

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-09-25T09:00:44+05:30  |  Updated On 25 Sept 2018 9:00 AM IST
    Bayer Subside Monsanto India appoints Cherukuri Ravishankar as new MD

    New Delhi: Seed firm Monsanto India, a subsidiary of Bayer group, has recently announced the appointment of Cherukuri Ravishankar as the Managing Director for its businesses in India, Bangladesh and Sri Lanka. This is the first major change in Monsanto India after German pharma and chemical major Bayer AG in June this year completed the USD 63 billion mega-deal to acquire US-based biotech major Monsanto.





    Ravishankar will replace Shilpa Divekar Nirula, who now moves on to a senior leadership position at the parent company Bayer, Monsanto India said in a statement.

    However, she would continue to remain a non-executive director of the company.

    "Ravishankar, who has earlier been a non-executive director of the company, has been instrumental in conceptualising and implementing strategic initiatives in commercial and modernising supply chain operations of the company," the statement said.

    He brings with him 21 years of experience across multiple functions including commercial, strategy and supply chain as well as multiple industries agriculture inputs, consumer products, consumer durables and consulting.

    With a presence of more than six decades in India, Monsanto India is committed to helping Indian farmers produce more while conserving sustainably and to be successful.

    It focuses on maize (DEKALB®, India's largest selling hybrid maize seed brand) and agricultural productivity (Roundup®, the world's as well as India's largest selling glyphosate herbicide).


    agriculture inputsbayer groupCherukuri Ravishankarconsumer durables and consulting.consumer productsDEKALB®glyphosate herbicidehybrid maizeMonsantoRoundupSeed firmShilpa Divekar Nirula
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok